Abstract
Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH receptor activation. This drug is now available in the US and Europe for the treatment of acromegaly.
MeSH terms
-
Acromegaly / drug therapy
-
Animals
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Delayed-Action Preparations
-
Human Growth Hormone / analogs & derivatives*
-
Human Growth Hormone / chemistry*
-
Human Growth Hormone / pharmacology
-
Human Growth Hormone / therapeutic use
-
Humans
-
Injections, Subcutaneous
-
Receptors, Somatotropin / antagonists & inhibitors*
-
Structure-Activity Relationship
Substances
-
Delayed-Action Preparations
-
Receptors, Somatotropin
-
Human Growth Hormone
-
pegvisomant